What question did this study set out to answer?

This research aims to characterize the prognostic significance of CEBPA mutations in myelodysplastic syndromes (MDS).

July 3, 2026CancersOpen Access

Clinical and Prognostic Significance of CEBPA Mutations in Myelodysplastic Syndromes

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals inferior survival in myelodysplastic syndromes with CEBPA mutations, suggesting implications for clinical assessment.

This research aims to characterize the prognostic significance of CEBPA mutations in myelodysplastic syndromes (MDS).
Analyzed 2,442 patients from the IWG 2022 MDS registry with exclusions for clarity.
Compared overall survival (OS) and leukemia-free survival (LFS) between CEBPA-mutated (n=66) and wild-type patients.
Used Kaplan–Meier estimation and Cox proportional hazards regression to adjust for confounding factors.
CEBPA-mutated patients had significantly inferior OS (median 17.2 months vs 42.2 months; HR 2.05, 95% CI 1.50–2.79; p < 0.001).
After adjusting for IPSS-R, the hazard ratio indicated adverse outcomes (HR 1.39, 95% CI 1.00–1.94; p=0.053).
Truncating mutations were linked to the adverse effects (HR 2.21; p = 0.023), while bZIP domain mutations showed no significant impact (HR 1.25; p = 0.470).

Khamis et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

July 3, 2026CancersOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals inferior survival in myelodysplastic syndromes with CEBPA mutations, suggesting implications for clinical assessment.

This research aims to characterize the prognostic significance of CEBPA mutations in myelodysplastic syndromes (MDS).
Analyzed 2,442 patients from the IWG 2022 MDS registry with exclusions for clarity.
Compared overall survival (OS) and leukemia-free survival (LFS) between CEBPA-mutated (n=66) and wild-type patients.
Used Kaplan–Meier estimation and Cox proportional hazards regression to adjust for confounding factors.
CEBPA-mutated patients had significantly inferior OS (median 17.2 months vs 42.2 months; HR 2.05, 95% CI 1.50–2.79; p < 0.001).
After adjusting for IPSS-R, the hazard ratio indicated adverse outcomes (HR 1.39, 95% CI 1.00–1.94; p=0.053).
Truncating mutations were linked to the adverse effects (HR 2.21; p = 0.023), while bZIP domain mutations showed no significant impact (HR 1.25; p = 0.470).

Khamis et al. (2026) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark